 CAMBRIDGE, Mass., Dec. 09, 2022 GLOBE NEWSWIRE Biogen Inc. Nasdaq: BIIB announced that the U.S. Food and Drug Administration FDA has accepted for review the abbreviated Biologics License Application aBLA for BIIB800, a biosimilar candidate referencing ACTEMRA1 tocilizumab, an anti-interleukin-6 receptor monoclonal antibody. ACTEMRA is indicated for several indications, including moderate to severe ... The post FDA Accepts Biogen Biologics License Application for BIIB800, A Biosim... 